Affiliate Disclosure: This desk has no financial relationship with any vendor. There are no affiliate links on this site. Retatrutide is not FDA-approved for any indication. Full disclosure & methodology
Retatrutide is not approved by the FDA for any medical use. Vendors making outcome or weight-loss claims may be in violation of federal law.
Monday, June 2, 2026 — Investigations Desk Desk active

Best Reta Vendors

Consumer-protection watchdog — retatrutide market
Active Investigation — Claims Audit

Inside the reta vendors selling outcome claims the FDA never approved

We catalogued 28 retatrutide sellers, documented their marketing language, and ran each claim against FDA-approved indications. Six vendors are making weight-loss or therapeutic statements the law does not permit. Screenshots below are dated and archived.

Investigation active
Retatrutide vials alongside a certificate of analysis showing compound identity testing on a research lab bench
Reta vials and COA documentation photographed during third-party procurement audit, May 2026. Identity confirmed; marketing claims on vendor site were a separate matter entirely.
Logged claim screenshots — hero evidence
28 vendors screenedOngoing documentation
140+ screenshots archivedDated & hashed on capture
Zero vendor revenueNo affiliate links, ever
Medically reviewedMD & PharmD on staff

Open investigations

All case files →

Vendor risk table

How scores are built →
Vendor Risk Score Claim Violations COA Status Regulatory History Investigation Status Last Logged
NovaPeptide Supplynovapep-supply.com 91 Weight-loss outcome claim; "clinically proven" language; implied FDA clearance Undated; lab not accredited No warning letter on record; FTC pattern Open Jun 1, 2026
RetaMax Directretamax-direct.com 84 Disease-treatment claim; "GLP-1 equivalent" comparison Duplicate COA across 3 batches Complaints filed — under review Open May 29, 2026
Reta Global Directretaglobaldirect.com 79 Before/after testimonials; "FDA-like purity" phrasing Generic template COA; no batch traceability Three consumer complaints logged Open May 24, 2026
PurePeptide Labspurepeptidelabs.io 61 Ambiguous benefit language ("supports metabolic health") Undated COA; lab named but batch unclear No history on record Watch May 22, 2026
Helix Research Co.helixresearchco.com 47 Human dosing protocols in blog; research-only header contradicted Per-lot COA; accreditation unverified No formal complaints Watch May 18, 2026
Meridian BioSystemsmeridianbio.net 39 One instance of patient-outcome language (removed after notice) COA provided on request; accredited lab Responded promptly; claim removed Watch May 10, 2026
Apex Biocompoundsapexbiocompounds.com 18 No therapeutic claims; research framing throughout Batch-linked HPLC; accredited third-party lab No complaints; proactive disclosure Clear May 15, 2026
AxisPeptide Researchaxispeptide.com 22 Research-only language; no outcome framing Per-lot COA; mass spec confirmed No flags on record Clear May 12, 2026

Higher score = higher documented risk. This desk does not recommend any vendor. Scores reflect claim severity and documentation integrity, not product quality. Retatrutide is not FDA-approved for any indication.

Claim screenshot log

Full archive →
Screenshot of vendor product page showing the text 'clinically shown to reduce body weight' captured May 14, 2026 Flagged
NovaPeptide Supply
"Clinically shown to reduce body weight up to 24% in 12 weeks" — product listing page, hero section
Screenshot showing same COA document provided for two separately purchased lots with different shipping dates Flagged
RetaMax Direct
Identical COA (same date, batch ID, and lab reference) delivered with orders placed 41 days apart
Screenshot showing before and after comparison images used on vendor testimonials page Under Review
Reta Global Direct
Before/after body composition photos presented alongside product listings — implied outcome endorsement
Screenshot of vendor blog post containing milligram dosing chart labeled for human weekly administration Under Review
Helix Research Co.
Blog post titled "Reta Protocol 2026" contains mg/kg dosing chart with human weight ranges and weekly escalation schedule
Screenshot of vendor page displaying FDA logo adjacent to product photography without indicating non-approval Flagged
NovaPeptide Supply
FDA seal-style graphic placed adjacent to product photography — no disclaimer that compound is not FDA-approved
Screenshot of vendor checkout page showing 'pharmaceutical grade' label on product with no regulatory basis Under Review
PurePeptide Labs
"Pharmaceutical grade retatrutide" used in product title and checkout flow — "pharmaceutical grade" has no regulatory definition for unapproved research compounds

How we score risk

Claim language audit

We capture all visible marketing copy across product pages, blog posts, email sequences, and social profiles. Each phrase is evaluated against FDA guidance on structure/function claims and unapproved drug marketing for research compounds.

Weight: 40% of total score

COA documentation integrity

We purchase product, request the COA, and verify: (a) the lab is independently accredited; (b) the batch number on the COA matches the product shipped; (c) the COA date is consistent with the lot timeline. Generic, re-used, or undated certificates are scored as a documentation gap.

Weight: 30% of total score

Regulatory history

We cross-reference FDA warning letter databases, FTC enforcement actions, and Better Business Bureau complaint logs. Prior enforcement history increases score weight. Responsive behavior — removing flagged claims after notice — reduces the multiplier.

Weight: 20% of total score

Transparency and consumer protection

Refund policy clarity, contact information accessibility, conspicuous research-only disclaimers, and response to our written inquiries. Vendors that ignore documented notice receive no transparency credit.

Weight: 10% of total score
FDA regulatory status — mandatory disclosure

Retatrutide is not approved by the U.S. Food and Drug Administration for any medical indication, including obesity, diabetes, or metabolic disease. No vendor may lawfully market it for human use or make therapeutic claims about it under current U.S. law.

This desk documents vendor behavior. It does not provide medical advice, recommend any compound, or suggest that any vendor is safe or legal to purchase from. Consult a licensed physician before making any healthcare decisions.

Affiliate disclosure: This desk maintains zero financial relationships with vendors. There are no affiliate links on this site. All vendor purchases for evidence collection are funded independently by desk operations.

The investigations desk

Editorial standards →
Maya Torres, Lead investigator
Maya Torres
Lead investigator
Claims audit, regulatory monitoring, vendor correspondence
James Park, PharmD
James Park, PharmD
Pharmacist reviewer
COA integrity, labeling compliance, documentation fraud assessment
Dr. Raymond Osei
Dr. Raymond Osei, MD
Medical reviewer
Clinical claims review, regulatory boundary assessment, case sign-off
Sarah Chen, PhD
Sarah Chen, PhD
Research scientist
Analytical chemistry, COA verification, mass spectrometry protocol